Comprehensive Analysis of Epstein-Barr Virus LMP2A-Specific CD8 + and CD4 +T Cell Responses Restricted to Each HLA Class I and II Allotype Within an Individual
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Latent membrane protein 2A (LMP2A), a latent Ag commonly expressed in Epstein-Barr virus (EBV)-infected host cells, is a target for adoptive T cell therapy in EBV-associated malignancies. To define whether individual human leukocyte antigen (HLA) allotypes are used preferentially in EBV-specific T lymphocyte responses, LMP2A-specific CD8+ and CD4+ T cell responses in 50 healthy donors were analyzed by ELISPOT assay using artificial Ag-presenting cells expressing a single allotype. CD8+ T cell responses were significantly higher than CD4+ T cell responses. CD8+ T cell responses were ranked from highest to lowest in the order HLA-A, HLA-B, and HLA-C loci, and CD4+ T cell responses were ranked in the order HLA-DR, HLA-DP, and HLA-DQ loci. Among the 32 HLA class I and 56 HLA class II allotypes, 6 HLA-A, 7 HLA-B, 5 HLA-C, 10 HLA-DR, 2 HLA-DQ, and 2 HLA-DP allotypes showed T cell responses higher than 50 spot-forming cells (SFCs)/5×105 CD8+ or CD4+ T cells. Twenty-nine donors (58%) showed a high T cell response to at least one allotype of HLA class I or class II, and 4 donors (8%) had a high response to both HLA class I and class II allotypes. Interestingly, we observed an inverse correlation between the proportion of LMP2A-specific T cell responses and the frequency of HLA class I and II allotypes. These data demonstrate the allele dominance of LMP2A-specific T cell responses among HLA allotypes and their intra-individual dominance in response to only a few allotypes in an individual, which may provide useful information for genetic, pathogenic, and immunotherapeutic approaches to EBV-associated diseases.
Abstract
Latent membrane protein 2A (LMP2A), a latent Ag commonly expressed in Epstein-Barr virus (EBV)-infected host cells, is a target for adoptive T cell therapy in EBV-associated malignancies. To define whether individual human leukocyte antigen (HLA) allotypes are used preferentially in EBV-specific T lymphocyte responses, LMP2A-specific CD8+ and CD4+ T cell responses in 50 healthy donors were analyzed by ELISPOT assay using artificial Ag-presenting cells expressing a single allotype. CD8+ T cell responses were significantly higher than CD4+ T cell responses. CD8+ T cell responses were ranked from highest to lowest in the order HLA-A, HLA-B, and HLA-C loci, and CD4+ T cell responses were ranked in the order HLA-DR, HLA-DP, and HLA-DQ loci. Among the 32 HLA class I and 56 HLA class II allotypes, 6 HLA-A, 7 HLA-B, 5 HLA-C, 10 HLA-DR, 2 HLA-DQ, and 2 HLA-DP allotypes showed T cell responses higher than 50 spot-forming cells (SFCs)/5×105 CD8+ or CD4+ T cells. Twenty-nine donors (58%) showed a high T cell response to at least one allotype of HLA class I or class II, and 4 donors (8%) had a high response to both HLA class I and class II allotypes. Interestingly, we observed an inverse correlation between the proportion of LMP2A-specific T cell responses and the frequency of HLA class I and II allotypes. These data demonstrate the allele dominance of LMP2A-specific T cell responses among HLA allotypes and their intra-individual dominance in response to only a few allotypes in an individual, which may provide useful information for genetic, pathogenic, and immunotherapeutic approaches to EBV-associated diseases.
참고문헌 (47)
- Lam JK, "Emergence of CD4+ and CD8+ polyfunctional T cell responses against immunodominant lytic and latent EBV antigens in children with primary EBV infection", Front Microbiol, 9, pp.416~ (2018)
- Calarota SA, "Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay", Immunology, 139, pp.533~544 (2013)
- Portis T, "Epstein-Barr virus(EBV)LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras", PI3K, Oncogene, pp.2004, 23[DOI]
- Deacon EM, "Epstein-Barr virus and Hodgkin’s disease : transcriptional analysis of virus latency in the malignant cells", J Exp Med, 177, pp.339~349 (1993)
- Sohn DH, "Measurement of CD8+ and CD4+ T cell frequencies specific for EBV LMP1 and LMP2A using mRNA-transfected DCs", PLoS One, 10, pp.e0127899~ (2015)
- Alber G, "Molecular mimicry of the antigen receptor signalling motif by transmembrane proteins of the Epstein-Barr virus and the bovine leukaemia virus", Curr Biol, 3, pp.333~339 (1993)
- Mancao C, "Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival", Blood, 110, pp.3715~3721 (2007)
- Callan MF, "The evolution of antigen-specific CD8+ T cell responses after natural primary infection of humans with Epstein-Barr virus", Viral Immunol, 16, pp.3~16 (2003)
- Xue Q, "Efficacy of recombinant adenovirus expressing a fusion gene from GM-CSF and Epstein-Barr virus LMP2A in a mouse tumor model", Hum Vaccin Immunother, 13, pp.2260~2268 (2017)
- Portis T, "Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during B-lymphocyte development", J Virol, 77, pp.105~114 (2003)
- Redchenko IV, "Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells", J Virol, 73, pp.334~342 (1999)
- Wang B, "Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes", Cell Mol Immunol, 6, pp.97~103 (2009)
- Lautscham G, "Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2", J Virol, 77, pp.2757~2761 (2003)
- Callan MF, "Large clonal expansions of CD8+ T cells in acute infectious mononucleosis", Nat Med, 2, pp.906~911 (1996)
- Steven NM, "Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response", J Exp Med, 185, pp.1605~1617 (1997)
- Janssen EM, "CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes", Nature, 421, pp.852~856 (2003)
- Shedlock DJ, "Requirement for CD4 T cell help in generating functional CD8 T cell memory", Science, 300, pp.337~339 (2003)
- Long HM, "CD4+ T-cell responses to Epstein-Barr virus(EBV)latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines", J Virol, 79, pp.4896~4907 (2005)
- Haigh TA, "EBV latent membrane proteins(LMPs)1 and 2 as immunotherapeutic targets : LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines", J Immunol, 180, pp.1643~1654 (2008)
- Krensky AM, "The HLA system, antigen processing and presentation", Kidney Int Suppl, 58, pp.S2~S7 (1997)
- Gebe JA, "HLA class II peptide-binding and autoimmunity", Tissue Antigens, 59, pp.78~87 (2002)
- Chelvanayagam G, "A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities", Immunogenetics, 45, pp.15~26 (1996)
- Falk K, "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules", Nature, 351, pp.290~296 (1991)
- Augusto DG, "HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection", Curr Opin Immunol, 76, pp.102178~ (2022)
- Lenz TL, "Excess of deleterious mutations around HLA genes reveals evolutionary cost of balancing selection", Mol Biol Evol, 33, pp.2555~2564 (2016)
- Hyun SJ, "Comprehensive analysis of cytomegalovirus pp65 antigen-specific CD8+ T cell responses according to human leukocyte antigen class I allotypes and intraindividual dominance", Front Immunol, 8, pp.1591~ (2017)
- Hyun YS, "Comprehensive analysis of CD4+ T cell responses to cmv pp65 antigen restricted by single HLA-DR, -DQ, and-DP allotype within an individual", Front Immunol, 11, pp.602014~ (2021)
- Baek IC, "Allele and haplotype frequencies of human leukocyte antigen-A, -B, -C, -DRB1, -DRB3", 4, PLoS One, pp.2021, 16[DOI]
- Hyun YS, "Comprehensive analysis of CD4+ T cell response cross-reactive to SARS-CoV-2 antigens at the single allele level of HLA class II", Front Immunol, 12, pp.774491~ (2022)
- Snary D, "Molecular structure of human histocompatibility antigens : the HLA-C series", Eur J Immunol, 7, pp.580~585 (1977)
- Kiepiela P, "Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA", Nature, 432, pp.769~775 (2004)
- Grifoni A, "Characterization of magnitude and antigen specificity of HLA-DP, DQ, and DRB3", 4, Front Immunol, pp.2019, 10[DOI]
- Robinson J, "IPD-IMGT", HLA database, 2020, pp.48, D948~D955
- Weiskopf D, "Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 339 adults from Managua, Nicaragua", Hum Immunol, 79, pp.1~2 (2018)
- Brooks CF, "Differential MHC class II expression on human peripheral blood monocytes and dendritic cells", Immunology, 63, pp.303~311 (1988)
- Lee J, "The MHC class II antigen presentation pathway in human monocytes differs by subset and is regulated by cytokines", PLoS One, 12, pp.e0183594~ (2017)
- Pender MP, "Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis", JCI Insight, 3, pp.e124714~ (2018)
- Smith C, "Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression", J Virol, 83, pp.6192~6198 (2009)
- Jones K, "The impact of HLA class I and EBV latency-II antigen-specific CD8+ T cells on the pathogenesis of EBV+ Hodgkin lymphoma", Clin Exp Immunol, 183, pp.206~220 (2016)
- Day EK, "Rapid CD8+ T cell repertoire focusing and selection of high-affinity clones into memory following primary infection with a persistent human virus : human cytomegalovirus", J Immunol, 179, pp.3203~3213 (2007)
- Schober K, "Reverse TCR repertoire evolution toward dominant low-affinity clones during chronic CMV infection", Nat Immunol, 21, pp.434~441 (2020)
- Hislop AD, "Epitope-specific evolution of human CD8+ T cell responses from primary to persistent phases of Epstein-Barr virus infection", J Exp Med, 195, pp.893~905 (2002)
- Jiang X, "Identifying coevolutionary patterns in human leukocyte antigen(HLA)molecules", Evolution, 64, pp.1429~1445 (2010)
- Markov PV, "Evolution and diversity of the human leukocyte antigen(HLA)", Evol Med Public Health, 2015, pp.1~ (2015)
- Jeffery KJ, "Do infectious diseases drive MHC diversity?", Microbes Infect, 2, pp.1335~1341 (2000)
- Prockop S, "Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation", J Clin Invest, 130, pp.733~747 (2020)
- O’Reilly RJ, "Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction", Bone Marrow Transplant, 54, pp.759~764 (2019)